Effect of high-dose oral Acetyl-L-carnitine versus placebo on serum level of oxidative and nirtosative stress and clinical outcomes in patients with ischemic stroke

Effect of high-dose oral Acetyl-L-carnitine versus placebo on serum level of oxidative and nirtosative stress and clinical outcomes in patients with ischemic stroke: a double-blind randomized clinical trialApproved

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150629022965N17

Enrollment

Registered

2018-07-25

Start date

2018-07-21

Completion date

Unknown

Last updated

2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ischemic stroke. Cerebral infarction

Interventions

Intervention 1: Intervention group: In the intervention group, patients will receive oral Acetyl-l-Carnitine, one 500mg capsule, at the dose of 1 g three times a day (every 8 hours) for 3 days in addi

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 18 to 85 years old Ischemic stroke Stroke for the first time Local neurologic disorder Patients who have been admitted for the first 24 hours after the stroke

Exclusion criteria

Exclusion criteria: Pregnancy or breastfeeding Inflammatory disease Asthma History of anaphylaxis shock

Design outcomes

Primary

Measure	Time frame
Serum level of lipid peroxidation. Timepoint: Before intervention and 3 days after intervention. Method of measurement: kit.;Serum levels of nitric oxide. Timepoint: Before intervention and 3 days after. Method of measurement: kit.;Serum levels of total antioxidant capacity. Timepoint: Before intervention and 3 days after. Method of measurement: kit.;Catalase activity. Timepoint: Before intervention and 3 days after intervention. Method of measurement: kit.;Activity of superoxide dismutase. Timepoint: Before intervention and 3 days after intervention. Method of measurement: kit.;Serum level of thiol. Timepoint: Before intervention and 3 days after intervention. Method of measurement: kit.;Activity of Glutathione Peroxidase. Timepoint: Before intervention and 3 days after intervention. Method of measurement: kit.;National Institutes of Health Stroke Scale. Timepoint: Before intervention and 90 days after intervention. Method of measurement: Questionnaire.;Modified Rankin Scale for Neurologic Disability. Timepoint: Before intervention and 90 days after intervention. Method of measurement: Questionnaire.	—

Measure

Time frame

Serum level of lipid peroxidation. Timepoint: Before intervention and 3 days after intervention. Method of measurement: kit.;Serum levels of nitric oxide. Timepoint: Before intervention and 3 days after. Method of measurement: kit.;Serum levels of total antioxidant capacity. Timepoint: Before intervention and 3 days after. Method of measurement: kit.;Catalase activity. Timepoint: Before intervention and 3 days after intervention. Method of measurement: kit.;Activity of superoxide dismutase. Timepoint: Before intervention and 3 days after intervention. Method of measurement: kit.;Serum level of thiol. Timepoint: Before intervention and 3 days after intervention. Method of measurement: kit.;Activity of Glutathione Peroxidase. Timepoint: Before intervention and 3 days after intervention. Method of measurement: kit.;National Institutes of Health Stroke Scale. Timepoint: Before intervention and 90 days after intervention. Method of measurement: Questionnaire.;Modified Rankin Scale for Neurologic Disability. Timepoint: Before intervention and 90 days after intervention. Method of measurement: Questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Mehrpooya

Hamedan University of Medical Sciences

m_mehrpooya2003@yahoo.com+98 81 3838 0717

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 13, 2026